Beyond DNA repair: the novel immunological potential of PARP inhibitors

被引：22

作者：

Chabanon, Roman M. ^{[1
,2
,3
,4
]}

Soria, Jean-Charles ^{[1
]}

Lord, Christopher J. ^{[3
,4
]}

Postel-Vinay, Sophie ^{[1
,2
,5
]}

机构：

[1] Univ Paris Sud, Univ Paris Saclay, Fac Med, Le Kremlin Bicetre, France

[2] Gustave Roussy, ATIP Avenir Grp, Inserm Unit U981, Villejuif, France

[3] Inst Canc Res, Breast Canc Now Toby Robins Breast Canc Res Ctr, London, England

[4] Inst Canc Res, CRUK Gene Funct Lab, London, England

[5] Gustave Roussy, DITEP, Villejuif, France

来源：

MOLECULAR & CELLULAR ONCOLOGY | 2019年 / 6卷 / 02期

关键词：

DNA damage response; DNA repair defects; PARP inhibitors; cGAS/STING; tumour cell-intrinsic immunity;

D O I：

10.1080/23723556.2019.1585170

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, confer sensitivity to poly-(ADP-ribose) polymerase inhibitors (PARPi). Our work, and that of others, shows that PARPi selectively trigger tumor cell-autonomous immune phenotypes in ERCC1- or BRCA-defective contexts. This suggests that PARPi, used in appropriately selected populations, might mediate their therapeutic effects by potentiating anti-tumor immunity.

引用

页数：4

共 11 条

[1]

Chabanon RM, 2019, J CLIN INVEST

[2] Mutational Landscape and Sensitivity to Immune Checkpoint Blockers [J].

Chabanon, Roman M. ;

Pedrero, Marion ;

Lefebvre, Celine ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Postel-Vinay, Sophie .

CLINICAL CANCER RESEARCH, 2016, 22 (17) :4309-4321

[3] PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer [J].

Ding, Liya ;

Kim, Hye-Jung ;

Wang, Qiwei ;

Kearns, Michael ;

Jiang, Tao ;

Ohlson, Carolynn E. ;

Li, Ben B. ;

Xie, Shaozhen ;

Liu, Joyce F. ;

Stover, Elizabeth H. ;

Howitt, Brooke E. ;

Bronson, Roderick T. ;

Lazo, Suzan ;

Roberts, Thomas M. ;

Freeman, Gordon J. ;

Konstantinopoulos, Panagiotis A. ;

Matulonis, Ursula A. ;

Zhao, Jean J. .

CELL REPORTS, 2018, 25 (11) :2972-+

[4] Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy [J].

Ferrara, Roberto ;

Mezquita, Laura ;

Texier, Matthieu ;

Lahmar, Jihene ;

Audigier-Valette, Clarisse ;

Tessonnier, Laurent ;

Mazieres, Julien ;

Zalcman, Gerard ;

Brosseau, Solenn ;

Le Moulec, Sylvestre ;

Leroy, Laura ;

Duchemann, Boris ;

Lefebvre, Corentin ;

Veillon, Remi ;

Westeel, Virginie ;

Koscielny, Serge ;

Champiat, Stephane ;

Ferte, Charles ;

Planchard, David ;

Remon, Jordi ;

Boucher, Marie-Eve ;

Gazzah, Anas ;

Adam, Julien ;

Bria, Emilio ;

Tortora, Giampaolo ;

Soria, Jean-Charles ;

Besse, Benjamin ;

Caramella, Caroline .

JAMA ONCOLOGY, 2018, 4 (11) :1543-1552

[5] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[6] Mitotic progression following DNA damage enables pattern recognition within micronuclei [J].

Harding, Shane M. ;

Benci, Joseph L. ;

Irianto, Jerome ;

Discher, Dennis E. ;

Minn, Andy J. ;

Reenberg, Roger A. G. .

NATURE, 2017, 548 (7668) :466-+

[7] PARP inhibitors: Synthetic lethality in the clinic [J].

Lord, Christopher J. ;

Ashworth, Alan .

SCIENCE, 2017, 355 (6330) :1152-1158

[8]

Parkes EE, 2017, JNCI-J NATL CANCER I, V109, P110, DOI DOI 10.1093/jnci/djx007

[9] A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer [J].

Postel-Vinay, S. ;

Bajrami, I. ;

Friboulet, L. ;

Elliott, R. ;

Fontebasso, Y. ;

Dorvault, N. ;

Olaussen, K. A. ;

Andre, F. ;

Soria, J-C ;

Lord, C. J. ;

Ashworth, A. .

ONCOGENE, 2013, 32 (47) :5377-5387

[10]

Robillard L, 2017, P AACR ANN M 2017 WA

← 1 2 →